Apogee Therapeutics

And that’s a wrap! Thank you to all who stopped by to see the Apogee team at #AAD2025 this weekend. If you missed us, check out our pipeline and publications on our website here. https://lnkd.in/e872jDBx

We are excited to meet new colleagues and reconnect with others at #AAD2025 this weekend! Visit Booth #2961 to learn more about our clinical pipeline and antibody half-life extension technology.

The Apogee Therapeutics team is excited to have a strong presence at #AAD2025 this week! Stop by Booth #2961 and say hello. Thanks to the American Academy of Dermatology for hosting our team!

We are pleased to update our pipeline progress and report full year 2024 financial results. 2024 was a productive year for Apogee, and we look forward to continuing to capitalize on that momentum throughout 2025. Learn more: https://lnkd.in/e2CNDyS3

Today, we are excited to announce positive Phase 1 interim results from the healthy volunteer study of APG990, exceeding all trial objectives and supporting its potential as a first-in-class combination therapy as part of APG279 (APG777 + APG990) for the treatment of atopic dermatitis (#eczema) and other inflammatory diseases. For more details on these promising data, we invite you to join our conference call this morning at 8:30AM ET. Full details here. https://lnkd.in/eHfc4rGX

This Monday, March 3, we will report interim results from the Phase 1 APG990 healthy volunteer trial. We invite those interested to join us at 8:30AM ET following the announcement for a conference call and webcast to discuss the results and plans for our combination approach for APG777 + APG990. Full details here. https://lnkd.in/ejGSWcds

We look forward to joining TD Cowen and Leerink at their healthcare investor events in March. Find more details here. https://lnkd.in/g6i3RduE

At Apogee, we believe real change happens when we invest in the future. In honor of International Day of Women and #GirlsInScience this week, we are putting our CORE values (Caring, Original, Resilient, Egoless) into action by supporting Girlstart and Black Girls Do STEM, organizations dedicated to encouraging and empowering young women in #STEM. These contributions, made on behalf of our Women@Apogee group and with the support of our leadership team, reflect our commitment to fostering an inclusive, diverse, and equitable scientific community. By breaking barriers and creating opportunities, we help ensure that the next generation of #WomenInScience and innovators have the resources they need to thrive.

At Apogee, we recognize that diversity drives innovation. Today, on International Day of Women and #GirlsInScience, we celebrate the brilliant minds shaping the future of biotechnology and the women whose discoveries are transforming healthcare, sustainability, and beyond.   From pioneering research to groundbreaking discovery, #WomenInSTEM continue to push the boundaries of what is possible. But while progress has been made, we know there’s more work to do to ensure equal opportunities and representation in STEM fields. This year, we reaffirm our commitment to supporting women in science through mentorship, inclusive hiring, and fostering a culture where every scientist, regardless of gender, can thrive.   To all the girls and #WomenInScience – your work matters, your voice is powerful, and your impact is immeasurable. Keep inspiring and innovating!

We are pleased to announce that the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe atopic dermatitis (#eczema), and that enrollment has been completed in the Part A portion of the trial. We expect to share Part A 16-week proof-of-concept data in mid-2025. Read about this milestone from CMO Carl Dambkowski below, and learn more here. https://lnkd.in/er-PkC8Y